Compare CREX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREX | IXHL |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 37.0M |
| IPO Year | 2015 | 2024 |
| Metric | CREX | IXHL |
|---|---|---|
| Price | $2.93 | $3.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.6K | ★ 81.5K |
| Earning Date | 04-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,437,000.00 | $12,000.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.21 | $0.16 |
| 52 Week High | $4.42 | $6.39 |
| Indicator | CREX | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | N/A |
| Support Level | $2.56 | N/A |
| Resistance Level | $3.74 | N/A |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 17.35 | 0.00 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.